MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.

Retina · 2019 · PMC6510321 · PMID 29370035

Europe PMC DOI

hedged sentence

0.0003

closest p · 0.0× alpha

0.0003

boldest claim

The sentences

highly significantP = 0.0003actually significant

The intereye concordance of MA in the study eye and in the fellow eye at year two was highly significant ( P = 0.0003).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.